TABLE 1.

Patient Population

Variable	All patients	Responders	Nonresponders^*	P^†
n	55	25	30	—
Age (y)	73 (67–79)	72 (74–76)	73 (64–79)	0.26
PSA	84 (22–307)	55 (19–146)	205 (30–565)	0.077
Hemoglobin (g/dL)	11 (10.1–12.1)	11.5 (10.6–13.1)	10.4 (10–11.4)	0.069
ANC (tsd/μL)	3.7 (3.2–4.8)	3.5 (2.7–4.4)	3.9 (3.2–4.8)	0.169
Platelets (tsd/μL)	233 (153–260)	209 (158–240)	236 (156–309)	0.098
Previous chemotherapy
Yes	34 (62%)	15 (60%)	19 (63%)	0.927
No	21 (38%)	10 (40%)	11 (37%)
Previous ²²³RaCl₂ (Xofigo; Bayer)
Yes	7 (13%)	4 (16%)	3 (10%)	0.506
No	48 (87%)	21 (84%)	27 (90%)
Previous treatments	3 (0–6)	3 (0–6)	3 (0–6)	0.93
PSMA cycles	3 (2–8)	4 (2–8)	2 (2–6)	0.006
Metastases
LNM	43 (78%)	21 (84%)	22 (73%)	0.34
BM	43 (78%)	16 (64%)	27 (90%)	0.02
Organ	14 (26%)	6 (24%)	8 (27%)	0.82
Tumor volume (mL)
LNM	25 (9.14–67.8)	27 (11.1–94.3)	19.7 (6.9–53.2)	0.62
BM	237 (58.9–525.8)	145 (50.5–569.7)	248.9 (81.8–489)	0.94
Organ	34 (9.82–52.7)	32.8 (15.5–38.1)	42 (7.9–56.9)	0.51

↵* This group includes both nonresponders and partial responders.
↵† Obtained by different statistical tests (see Materials and Methods).
ANC = absolute neutrophil count; tsd = thousand.
Continuous data are median and range; qualitative data are number and percentage.